CO5060482A1 - Derivados terapeuticos de biarilo - Google Patents

Derivados terapeuticos de biarilo

Info

Publication number
CO5060482A1
CO5060482A1 CO99036228A CO99036228A CO5060482A1 CO 5060482 A1 CO5060482 A1 CO 5060482A1 CO 99036228 A CO99036228 A CO 99036228A CO 99036228 A CO99036228 A CO 99036228A CO 5060482 A1 CO5060482 A1 CO 5060482A1
Authority
CO
Colombia
Prior art keywords
carbon atoms
alkyl
cyano
alkoxy
atoms
Prior art date
Application number
CO99036228A
Other languages
English (en)
Inventor
Kelly Horne Donaldson
Barry George Shearer
David Edward Uehling
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO5060482A1 publication Critical patent/CO5060482A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un compuesto de la fórmula (I) o un derivado farmacéuticamenteaceptable del mismo:caracterizado porque R1 es un grupo fenilo, naftilo, piridilo, tiazolilo, fenoximetilo o pirimidilo, opcionalmente sustituido por uno o más sustituyentes seleccionados del grupo que consiste de halógeno, hidroxi, alcoxi, alcoxi de 1 a 6 átomos de carbono, alquilo de 1 a 6 átomos de carbono, nitro, ciano, hidroximetilo, trifluorometilo, -NR6 R6 , y -NHSO2 R6 , donde cada R6 es independientemente hidrógeno oalquilo de 1 a 4 átomos de carbono;R2 es hidrógeno o alquilo de 1 a 6 átomos de carbono;X es oxígeno, azufre, -NH o -N-alquilo de 1 a 4 átomos de carbono;R3 es ciano, tetrazol-5-ilo o -CO2 R7 donde R7 es hidrógeno o alquilo de 1 a 6 átomos de carbono;R4 y R5 son independientemente hidrógeno, alquilo de 1 a 6 átomos de carbono, -CO2 H, -CO2 alquilo de 1 a 6 átomos de carbono, ciano, tetrazol-5-ilo, halógeno, trifluorometilo o alcoxi de 1 a 6 átomos de carbono o cuando R4 y R5 se unen a átomos de carbono adyacentes, R4 y R5 pueden, conjuntamente con los átomos de carbono a los cuales se unen, formar un anillo de 5 o 6 miembros, fusionado que contiene opcionalmente uno o dos átomos de nitrógeno, oxígeno o azufre; eY es N o CH.
CO99036228A 1998-06-13 1999-06-09 Derivados terapeuticos de biarilo CO5060482A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9812709.5A GB9812709D0 (en) 1998-06-13 1998-06-13 Chemical compounds

Publications (1)

Publication Number Publication Date
CO5060482A1 true CO5060482A1 (es) 2001-07-30

Family

ID=10833658

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99036228A CO5060482A1 (es) 1998-06-13 1999-06-09 Derivados terapeuticos de biarilo

Country Status (38)

Country Link
US (1) US6251925B1 (es)
EP (1) EP1087943B1 (es)
JP (1) JP3471754B2 (es)
KR (1) KR100415877B1 (es)
CN (1) CN1214008C (es)
AP (1) AP1687A (es)
AR (1) AR029301A1 (es)
AT (1) ATE302189T1 (es)
AU (1) AU753004B2 (es)
BR (1) BR9911182B1 (es)
CA (1) CA2334713C (es)
CO (1) CO5060482A1 (es)
CZ (1) CZ299172B6 (es)
DE (1) DE69926752T2 (es)
DK (1) DK1087943T3 (es)
EA (1) EA003641B1 (es)
EE (1) EE04435B1 (es)
EG (1) EG23856A (es)
ES (1) ES2245107T3 (es)
GB (1) GB9812709D0 (es)
HK (1) HK1034253A1 (es)
HR (1) HRP20000854B1 (es)
HU (1) HUP0102668A3 (es)
ID (1) ID27841A (es)
IL (2) IL140219A0 (es)
IS (1) IS2277B (es)
MY (1) MY119542A (es)
NO (1) NO318782B1 (es)
NZ (1) NZ508805A (es)
PE (1) PE20000726A1 (es)
PL (1) PL196943B1 (es)
RS (1) RS49921B (es)
SI (1) SI1087943T1 (es)
SK (1) SK286256B6 (es)
TR (1) TR200100299T2 (es)
TW (1) TWI244471B (es)
WO (1) WO1999065877A1 (es)
ZA (1) ZA200007417B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9929118D0 (en) * 1999-12-10 2000-02-02 Glaxo Group Ltd Chemical compounds
GB9929297D0 (en) * 1999-12-11 2000-02-02 Glaxo Group Ltd Process
DE10005150A1 (de) * 2000-02-07 2001-08-09 Merck Patent Gmbh Verfahren zur Herstellung von 5-Arylnicotinaldehyden
KR20030044013A (ko) 2000-10-20 2003-06-02 화이자 프로덕츠 인코포레이티드 알파-아릴 에탄올아민 및 이들의 베타-3 아드레날린성수용체 작용제로서의 용도
AR035605A1 (es) 2000-12-11 2004-06-16 Bayer Corp Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores
US7034053B2 (en) 2001-01-31 2006-04-25 Smithkline Beecham Corporation Phenethanolamine derivatives, compositions, and their use as agonists at atypical beta-adrenoreceptors
GB0102407D0 (en) 2001-01-31 2001-03-14 Glaxo Group Ltd Process
US7709677B2 (en) 2001-01-31 2010-05-04 Glaxosmithkline Llc Process of preparing arylethanoldiamines
GB0102408D0 (en) * 2001-01-31 2001-03-14 Glaxo Group Ltd Chemical compounds
EP1236723A1 (en) 2001-03-01 2002-09-04 Pfizer Products Inc. Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof
AR035858A1 (es) 2001-04-23 2004-07-21 Bayer Corp Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3
MXPA04001785A (es) 2001-09-14 2004-07-08 Bayer Ag Benzofurano y derivados de dihidrobenzofurano utiles como agonistas de beta-3 adrenoreceptores.
AU2003209527A1 (en) * 2002-02-27 2003-09-09 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
EP1478625A1 (en) * 2002-02-27 2004-11-24 Pfizer Products Inc. Processes and intermediates useful in preparing beta-3-adrenergic receptor agonists
DOP2003000587A (es) * 2002-02-27 2003-08-30 Pfizer Prod Inc AGONISTAS DEL RECEPTOR ß3-ADRENERGICO
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
AU2003248355A1 (en) * 2002-02-27 2003-09-09 Pfizer Products Inc. Salt of a pyridyl ethanolamine derivative and its use as a beta-3-adrenergic receptor agonist
MXPA05000663A (es) * 2002-07-17 2005-09-20 Lek Pharmaceuticals Derivados novedosos de piridiletanol (feniletil) aminas como inhibidores de la biosintesis de colesterol, proceso para su preparacion, y composiciones farmaceuticas que los contienen.
GB0220730D0 (en) * 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
ES2571779T3 (es) * 2002-12-13 2016-05-26 Ym Biosciences Australia Pty Inhibidores de cinasa a base de nicotinamida
CN100418944C (zh) * 2003-02-14 2008-09-17 橘生药品工业株式会社 氨基醇衍生物、含有所述氨基醇衍生物的药物组合物及其应用
KR20050100681A (ko) * 2003-02-14 2005-10-19 깃세이 야쿠힌 고교 가부시키가이샤 아미노알코올 유도체, 그것을 함유하는 의약조성물 및그들의 용도
US7417169B2 (en) 2003-10-24 2008-08-26 Kissei Pharmaceutical Co., Ltd. Amino alcohol derivatives, medicinal composition containing the same, and use of these
WO2005061433A2 (en) * 2003-12-23 2005-07-07 Astellas Pharma Inc. Aminoalcohol derivatives
US7915309B2 (en) * 2007-06-20 2011-03-29 Protia, Llc Deuterium-enriched oseltamivir
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
WO2010118291A2 (en) * 2009-04-10 2010-10-14 Auspex Pharmaceuticals, Inc. Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
MX353105B (es) 2010-08-03 2017-12-19 Velicept Therapeutics Inc Combinaciones de agonistas del receptor beta-3-adrenergico y antagonistas del receptor muscarinico para tratar vejiga hiperactiva.
AR089957A1 (es) 2012-02-09 2014-10-01 Altherx Inc Combinaciones farmaceuticas, combinaciones sinergicas
WO2014108449A1 (en) 2013-01-08 2014-07-17 Atrogi Ab A screening method, a kit, a method of treatment and a compound for use in a method of treatment
AU2015358378A1 (en) 2014-12-03 2017-06-29 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
US10065922B2 (en) * 2015-10-23 2018-09-04 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0006735B1 (en) * 1978-06-28 1983-06-15 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
GB8519154D0 (en) * 1985-07-30 1985-09-04 Ici Plc Aromatic ethers
DE3934436A1 (de) 1989-06-01 1991-04-18 Thomae Gmbh Dr K 2-hydroxy-n-propylamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5061727A (en) * 1990-05-04 1991-10-29 American Cyanamid Company Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles
NO179246C (no) 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
AU2737295A (en) * 1994-06-09 1996-01-04 Glaxo Group Limited Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists

Also Published As

Publication number Publication date
PE20000726A1 (es) 2000-08-24
CZ20004648A3 (en) 2001-06-13
EP1087943B1 (en) 2005-08-17
SK19082000A3 (sk) 2001-09-11
WO1999065877A1 (en) 1999-12-23
SK286256B6 (sk) 2008-06-06
IL140219A (en) 2006-07-05
AU4510399A (en) 2000-01-05
KR100415877B1 (ko) 2004-01-24
HUP0102668A2 (hu) 2001-12-28
IS2277B (is) 2007-09-15
TWI244471B (en) 2005-12-01
CA2334713A1 (en) 1999-12-23
NO318782B1 (no) 2005-05-09
HUP0102668A3 (en) 2002-11-28
AU753004B2 (en) 2002-10-03
ID27841A (id) 2001-04-26
CZ299172B6 (cs) 2008-05-07
EG23856A (en) 2007-11-11
HRP20000854B1 (en) 2006-05-31
US6251925B1 (en) 2001-06-26
CA2334713C (en) 2006-01-17
YU79200A (sh) 2003-01-31
CN1214008C (zh) 2005-08-10
NO20006319D0 (no) 2000-12-12
IS5760A (is) 2000-12-08
EE04435B1 (et) 2005-02-15
AP2001002028A0 (en) 2001-03-31
EA003641B1 (ru) 2003-08-28
NZ508805A (en) 2003-08-29
CN1312800A (zh) 2001-09-12
BR9911182B1 (pt) 2010-09-08
TR200100299T2 (tr) 2001-06-21
IL140219A0 (en) 2002-02-10
DE69926752D1 (de) 2005-09-22
EA200001172A1 (ru) 2001-08-27
HRP20000854A2 (en) 2001-12-31
DK1087943T3 (da) 2005-12-12
SI1087943T1 (sl) 2005-12-31
AR029301A1 (es) 2003-06-25
HK1034253A1 (en) 2001-10-19
PL344865A1 (en) 2001-11-19
AP1687A (en) 2006-12-04
JP2002518374A (ja) 2002-06-25
MY119542A (en) 2005-06-30
ZA200007417B (en) 2001-12-12
JP3471754B2 (ja) 2003-12-02
RS49921B (sr) 2008-09-29
PL196943B1 (pl) 2008-02-29
BR9911182A (pt) 2001-03-13
NO20006319L (no) 2001-02-09
GB9812709D0 (en) 1998-08-12
DE69926752T2 (de) 2006-02-02
EP1087943A1 (en) 2001-04-04
KR20010052791A (ko) 2001-06-25
EE200000744A (et) 2002-04-15
ATE302189T1 (de) 2005-09-15
ES2245107T3 (es) 2005-12-16

Similar Documents

Publication Publication Date Title
CO5060482A1 (es) Derivados terapeuticos de biarilo
EA200100755A1 (ru) 4-оксо-1,4-дигидро-3-хинолинкарбоксамиды как антивирусные агенты
ATE282614T1 (de) Phenylharnstoff und phenylthioharnstoffderivate
DK0383449T3 (da) Heterocykliske forbindelser
TW200643015A (en) 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
AR032453A1 (es) Derivados alquinil fenil heteroaromaticos activadores de glucoquinasa, un proceso para su preparacion, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de medicamentos
NO951633D0 (no) 5-arylindol-derivater og deres anvendelse som serotonin (5-HT1) agonister
ATE139233T1 (de) Annelierte thiophen-derivate, ihre herstellung und verwendung
CO5690593A2 (es) Nuevos derivados de pirimidin 2-amina
PE20001083A1 (es) Derivados de mononitrato de isosorbide
ES2137512T3 (es) Derivados de amidina biciclicos como inhibidores de la sintetasa de oxido nitrico.
ATE71619T1 (de) Pyridazinon-derivate.
CO5080785A1 (es) Derivados heterociclicos
ATE247660T1 (de) Furopyridinderivate und ihre therapeutische verwendung
FR2479219B1 (es)
AR027035A1 (es) Pirroles sustituidos
CO4950554A1 (es) Derivados de 1,3-dihidro o 3,4-dihidroisoquinolin-benzamida
ATE340155T1 (de) Medizinische anwendungen von phenylalkanolen und derivaten davon
HRP20080501T3 (en) Beta-lactams for the treatment of cns disorders
CO4940434A1 (es) Derivados terapeuticos de naftaleno
AR003129A1 (es) Derivados de bencimidazol 2-sustituidos y composiciones farmaceuticas que los comprenden
ES416988A1 (es) Procedimiento para la obtencion de 2-amino-4 h-piranos.
ECSP972301A (es) Triciclicos sustituidos